Asia Pharma R&D Leaders Summit 2017

Hits:1942   Date: 11/9/2016

Asia Pharma R&D Leaders Summit 2017

March.21 (Tuesday) – March. 22 (Wednesday). 2017

 IHG Shanghai Pudong Hotel, China

 

About APRDL 2017

 

The Asia Pharma R&D Leaders Summit 2017 ( APRDL 2017) will bring in fresh perspectives and scientific advancement on popular therapeutic areas in Neurodegenerative Diseases; Cancer, Diabetes and metabolic diseases which big pharma R&D are heavily investing in Asia. The new perspective will be discussed in parallel with pharma partnering models, licensing opportunities, risk management approaches, outsourcing strategies, Precision Medicine, IP management and latest pharma research advancement on sequencing, biomarkers, preclinical imaging, data management to optimize your pharma R&D cost efficiency and gain competitiveness in Asia. Come and join Asia Pharma R&D Leaders 2017 – the most premier pharma R&D event in China with Asia perspectives:

 

With this in mind, “ Asia Pharma R&D Leaders 2017 “ summit themes will cover:

 

 ★ Asian Strategies: How Big Pharma and Biotech companies manage their R&D activities

 ★ How can companies drive maximum value from M&A and licensing deals

 ★ Government initiatives in China 13^th 5 years’ plan benefit for your research projects in China

 ★ Explore mass in-licensing opportunities in Asia emerging markets in response to new world R&D order

 ★ Novel Technologies and Approaches for Drug Discovery

 ★ Precision Medicine & Personalized Healthcare

 ★ Research Ethics & Ethical Approval

 ★ Develop new business models in 2017 and beyond for pharma R&D geared toward cost efficiency and ROI improvement

 ★ Navigate Asia market trends for heavily invested therapeutics areas: Oncology, Neurodegenerative and Metabolic diseases

 ★ Lay foundations for effective partnership with top CROs, Biotech and Academia

 ★ Tapping into Funding & Investment Opportunities in Pharmaceutical R&D in Asia

 ★ Challenges of Conducting Clinical Trials in APAC, Regulatory Requirements & IRB Approval Process

 ★ Personalized anticancer drug discovery & development in Asia

 

Day 1 TUESDAY March 21, 2017

08:40 Chairman’s Opening Remarks

Optimizing and Strengthening Collaborations in Asia

08:50 Global R&D Leaders Round Table R&D Innovation & Partnership in China- Next Five Years and
beyond
This featured R&D Leaders roundtable discussion will explore the evolving future of innovative R&D in China: We have invited the leaders in Global R&D to share their vision and experience in promoting drug discovery innovation in Asia.

Moderator:
Tobias Gabriel
Ph.D. Head of External Science & Drug Discovery, Global Discovery Chemistry, Novartis Institutes for BioMedical Research (NIBR)

Panelists:
Uwe Schoenbeck,
Ph.D., SVP, Chief Scientific Officer, External R&D Innovation & CTI,WRD, Pfizer
Joern-Peter Halle
Ph.D., SVP, Head of External Innovation, Merck Biopharma
Soren Tullin,
Ph.D., Corporate Vice President, Discovery Biology & Technology, Novo Nordisk A/S
Benjamin Seet
Ph.D. Executive Director, Biomedical Research Council, Agency for Science,Technology and Research, Singapore
Mike Dethick
Ph.D., Managing Director, R&D-Based Pharmaceutical AssociationCommittee
Min Li,
Ph.D., Senior Vice President, Global Head of Neuroscience Therapy Area and General Manager, GSK R&D Center China
Dongmin Chen
Ph.D., Dean, School of Innovation and Entrepreneurship, Director, Office of Science & Technology Development Dongxu Chair Professor,Advanced Interdisciplinary Studies & School of Innovation and Entrepreneurship, Peking University

09:30 Regional R&D Leaders Round Table: Promoting Asia & China Innovation: Developing the Strategic and Innovative Partnership in Asia & China

Moderator:
Jim Li
Ph.D. CEO, Sundia MediTech Company

Panelists:
Binhui (Ben) Ni
Ph.D., AVP, Head, External Innovation & Partnering Strategy and Business Development, Asia Pacific, Sanofi
Tom Kinzel
Ph.D., Head of Drug Discovery, Innovation Centre China, Pharmaceuticals Division, Bayer
Mu Hua
Ph.D., CSO and President of R&D, Simcere Pharmaceutical Group
Bin Li
Ph.D., Director, Search and Evaluation JAPAC, Abbvie China
Bin Shi
Ph.D., Head of External R&D and Licensing, Amgen Asian R&D Center
Mingde Xia
Ph.D., Senior Director of Johnson & Johnson Innovation Center, Vice Chair of Asian Society of Innovation &
Achievement ( A.S.I.A )
Liming Shao
Ph.D., Director of Shanghai Center for Drug Discovery &Development (SCDDD), Fudan University

10:10 Accelerating Drug Discovery through A Fully Integrated Testing Platform Jason Liu, SVP and Chief Operating Officer, WuXi AppTec

10:40-11:10 COFFEE BREAK

11:10 Speeding Innovation in Pharma: The Global Partnering Imperative

Uwe Schoenbeck,
Ph.D., SVP, Chief Scientific Officer, External R&D Innovation & CTI, WRD,Pfizer

11:40 Singapore’s A*STAR: The role of Research and Technology Organizations in Open Innovation
This presentation will describe how public sector R&D investments, and in particular, how organizations like A*STAR or the Agency for Science,Technology and Research, have played a crucial role in developing the research ecosystem in Singapore, and in providing a link between academic research and economic value capture for the country. It will further highlight how A*STAR’s approach to open innovation has resulted in successful partnerships with both multinational and local companies, and
contributed towards improving health outcomes.

BENJAMIN SEET ,
Ph.D., Executive Director, Biomedical Research Council,Agency for Science, Technology and Research

12:10-13:30 Network Luncheon

Diabetes Therapeutics Research

14:00 Discovery and Evaluation of Peptides & Proteins for the Treatment of Type 2 Diabetes
The presentation will cover the unmet needs of type 2 diabetes as well as Novo Nordisk’s approach to evaluation of new targets from the public domain

Soren Tullin,
Ph.D., Corporate Vice President, Discovery Biology & Technology,Novo Nordisk A/S

14:30 Translational models of diabetes and complications in rodents and nonhuman primates:
applications in pharmaceutical research

Jim Wang,
Ph.D., Senior Vice President, Cardiovascular and Metabolic Diseases( CVMD) Research, CrownBio

Open Innovation & Investment for Pharma R&D

15:00 Keynote Presentation from Zai Lab Limited
Samantha Du
Chairman and Chief Executive Officer, Zai Lab Limited

15:00 Keynote on Open Innovation in University-Industrial Partnership for BioMedical Technology Development
Dongmin Chen
Ph.D., Dean, School of Innovation and Entrepreneurship, Director, Office of Science & Technology Development Dongxu Chair Professor, Advanced Interdisciplinary Studies & School of Innovation and Entrepreneurship,Peking University

16:00 Keynote on Academia-Industry Collaboration:Regional Opportunities with Global Outlook
Min Li,
Ph.D., SVP, Global Head of Neuroscience Therapy Area and General Manager, GSK R&D Center China

16:30 Keynote Spotlight Session Slot Henri Doods,
Henri Doods,
Ph.D., VP, Global Head of Research Beyond Borders, Boehringer
Ingelheim

17:00 Keynote on Bringing Excellence in Science to China --- Surfing the 13.5 Innovation Wave from MNC
Perspectives
Bin Jerica Shi,
Ph.D., Head of External R&D and Licensing, Amgen Asia R&D Center

17:30 Keynote on Challenges of Conducting Clinical Trials in APAC for Pharma and Med Device
• Drivers of trend for CT in APAC
• Mistakes made by Pharma in Emerging Markets
• Complex regulatory environment for Pharma and Med Device
• Regulatory Requirements & IRB approval Process in Asia

Timothy Low
M.D., Chief Executive Officer, Farrer Park Hospital, Singapore

18:00 DAY ONE Close

Day 2 WEDNESDAY MARCH 22, 2017

08:55 Chairman’s Opening Remarks

Emerging Therapeutics T2D Research Workshop

09:00 Future Type 2 Diabetes ( T2D ) treatment: where to go and how to get there
• What is the future trend for T2D Treatment
• What is the biology or drug target that may lead to the future T2D treatment
• What technology may lead to the future T2D treatment

09:30 Gastric Bypass Surgery for T2D Treatment
Dr. Wu Jiarui, Professor, Institute of Biochemistry and Cell Biology,Chinese Academy of Sciences
.
10:00 Keynote Academia Talk, Drug Discovery in China
Dr. Ming-wei Wang, Professor, Shanghai Institute of Materia Medica,Chinese Academy of Sciences, Director of the National Center for Drug Screening, Dean of School of Pharmacy, Fudan University

10:30 TEA & Coffee BREAK

11:00 Academia Talk: Basic Research & Translational Sciences
Dr. Rui-Ping Xiao, Professor, Director of IMM/PKU, Principal Investigator. Laboratory of Signal Transduction, Peking University
Prof. Aimin Xu, Director, State Key Laboratory of Pharmaceutical Biotechnology, HKU; Director, Antibody and Immunoassay Services,University of Hong Kong
Prof. Pingping Li, Professor, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College
Dr. Han Weiping, Deputy Director, Head Laboratory of Metabolic Medicine,SBIC, Research Director, MHDU, IMCB, Singapore A*Star

11:30 Future T2D Medicine Research Panel Discussion
Dr. Yi Zhang, Co-Founder, VP Clinical R&D, Hua Medicine
Dr. Ming-wei Wang, Professor, Shanghai Institute of Materia Medica,Chinese Academy of Sciences, Director of the National Center for Drug Screening, Dean of School of Pharmacy, Fudan University
Dr. Dongmin Chen, Dean, School of Innovation and Entrepreneurship,Director, Office of Science and Technology Department, Peking University
Dr. Fang Zhang, VP, Head of Discovery Biology and Technology China, Novo Nordisk Research Center China
Dr. Weiping Jia, President, Shanghai Sixth People’s Hospital, Jiaotong University

12:00-13:30 Network Luncheon

14:00 An Innovative Technology and Business Model to Develop First-in-class Drugs Globally with Precision
Medicine
Wen Luo
Founder and CEO, Denovo Biopharma

14:30-15:00 TEA BREAK AND NETWORKING

15:00 Panel Discussion: Chinese Biopharma R&D
Licensing Opportunities in 2016 to 2020 ( 13th 5-Yr Plan )
Hong Ling,Chief Scientific Officer, R&D Center, Sanhome Pharmaceuticals
Li Youxin,EVP, Head of R&D Center, Luye Pharmaceuticals
Xi Ning,Chief Scientific Officer, HEC Pharma
Kailing Guan,SVP, The Institute of Pharma R&D, Qilu Pharmaceuticals
Guochun Li,Chief Scientific Officer, Head of Biologics, Harbin Gloria Pharmaceuticals
Zhenkun Ma,Founder and CEO, TenNor Therapeutics Limited
Lan Jiong,General Manager, Haiyan Pharma – Yangtze River Pharmaceutical

15:30 Patent Extension: Licensing and Collaboration;IP Protection for Pharmaceutical R&D
Caihui Li,Chief IP Officer, 3S Guojian Pharmaceuitcal ( Shanghai ) Co., Ltd
David Shen,VP Legal, General Counsel, AstraZeneca China

16:00 Global Drug Discovery and Development– HengRui Experience
Lianshan Zhang,  President of Global R&D, Jiangsu Hengrui Medicine

16:30 Chairman’s Closing Remarks

16:45 Close of Day Two

Contact Us

Kevin Tan

Program Director

T: +86 21 6172 6970
C: +86 1366 1571 955

E: kevin.tan@deliver-consulting.com